Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 650 across all filing types
Latest filing 2022-02-15 Director's Dealing
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). It details the share acquisition (insider trading) by an executive (Lim Dong Soo) of GemVax & Kael. This type of filing is specifically categorized as a Director's Dealing (DIRS) report.
2022-02-15 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling of an Investor Relations (IR) event (Non-Deal Roadshow). It provides details such as the date, location, target audience, and purpose of the meeting. Since it is an announcement of an upcoming event rather than the presentation materials themselves, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a regulatory filing announcement.
2022-02-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the share ownership, changes in holdings, and special relationships of major shareholders (Gem & Company and related parties) in GemVax & KAEL. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-02-04 Korean
투자판단관련주요경영사항(알츠하이머병 치료제로서 GV 1001의 국내 제3상 임상시험계획 승인)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) regarding a material management decision, specifically the approval of a Phase 3 clinical trial for a drug. This type of disclosure is a standard regulatory announcement in the Korean market (KOSDAQ/KRX) regarding significant business developments. Since it does not fit into specific categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate disclosures.
2022-01-17 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) used to disclose insider trading or changes in share ownership by company directors and executives. Based on the provided definitions, this corresponds to 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2022-01-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status, changes in ownership, and contractual relationships (pledges, loans) of major shareholders. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2021-12-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.